92
Views
0
CrossRef citations to date
0
Altmetric
Short Communication

Poor Response to Direct-Acting Antiviral Therapy in HCV-Infected Elderly Population: A Real-Life Cohort Study Based on GeneXpert® Technology

, , , , , , , , , & show all
Pages 467-474 | Received 18 Dec 2017, Accepted 27 Apr 2018, Published online: 07 Jun 2018
 

Abstract

Aim: This study aimed to determine the efficacy of direct-acting antiviral drugs in different ethnicities and elderly population of Pakistan. Methods: We used GeneXpert® technology to quantify HCV RNA and evaluated treatment response in different cohorts that included HCV patients classified on the basis of their age-group and ethnicity. Results: The findings of our study suggest that 76% of nonresponder patients were older than 55 years of age which shows that age is the predictor of treatment outcome of direct-acting antiviral drugs. In addition to this, no differences were observed in overall efficacy by ethnicity. Conclusion: Treatment-regimen sofosbuvir+ribavirin has a limited effect on older patients; therefore, practitioners and healthcare professionals need to reconsider treatment options for elderly populations.

Acknowledgements

The authors gratefully acknowledge all members (M Khan, Anam, R Bashir, Nawaz, Zeeshan, Bilal, Riaz, Peer, and Raheel) of Genome Centre for Molecular based Diagnostics and Research, Lahore, Pakistan for their collaboration and technical support.

Financial & competing interests disclosure

The authors have no relevant affiliations or financialinvolvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

Ethical statement

Procedures followed in the study were in accordance with the ethical standards of institution’s committee.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.